Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Repligen Corporation
Repligen Corporation News
Repligen Corporation Quantitative Score

About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Repligen Corporation Financials
Table Compare
Compare RGEN metrics with: | |||
|---|---|---|---|
Earnings & Growth | RGEN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RGEN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RGEN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RGEN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Repligen Corporation Income
Repligen Corporation Balance Sheet
Repligen Corporation Cash Flow
Repligen Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Neutral |
| Return on Assets | Buy |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Repligen Corporation Executives
| Name | Role |
|---|---|
| Anthony J. Hunt | Executive Chair |
| Olivier Loeillot | President, Chief Executive Officer & Director |
| Jason K. Garland | Chief Financial Officer & Chief Compliance Officer |
| James R. Bylund | Chief Operating Officer |
| Ralf Kuriyel | Senior Vice President of Research & Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Anthony J. Hunt | Executive Chair | Male | 1964 | 1.39M |
| Olivier Loeillot | President, Chief Executive Officer & Director | Male | 1970 | 1.15M |
| Jason K. Garland | Chief Financial Officer & Chief Compliance Officer | Male | 1974 | 1.13M |
| James R. Bylund | Chief Operating Officer | Male | 1963 | 816.09K |
| Ralf Kuriyel | Senior Vice President of Research & Development | Male | 1958 | 635.39K |
Repligen Corporation Insider Trades
| Date | 4 Dec |
| Name | Hunt Anthony |
| Role | Director |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 2000 |
| Date | 25 Nov |
| Name | Loeillot Olivier |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 7041 |
| Date | 18 Nov |
| Name | Bylund James |
| Role | Chief Operating Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 2191 |
| Date | 13 Nov |
| Name | Hunt Anthony |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1784 |
| Date | 13 Nov |
| Name | Hunt Anthony |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 2100 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Dec | Hunt Anthony | Director | Disposed | J-Other | 2000 |
| 25 Nov | Loeillot Olivier | Chief Executive Officer | Disposed | S-Sale | 7041 |
| 18 Nov | Bylund James | Chief Operating Officer | Disposed | S-Sale | 2191 |
| 13 Nov | Hunt Anthony | Director | Disposed | S-Sale | 1784 |
| 13 Nov | Hunt Anthony | Director | Disposed | S-Sale | 2100 |